Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib

Table 2 Correlation of toxicities and tumor shrinkage with percentage change in plasma biomarkers

Plasma Biomarker	n	Hypertension		Proteinuria		Fatigue		Tumor Shrinkage
Plasma Biomarker	n	r	P Value	r	P Value	r	P Value	r	P Value
IL-6	19	0.19	.421	0.247	.294	-0.173	.465	-0.437	.061
IL-8	19	-0.077	.748	0.053	.823	0.002	.993	-0.191	.434
IL-10	19	0.158	.505	0.038	.872	0.141	.552	-0.392	.097
VEGF	19	0.569	.008^b	0.703	<.001^a	0.529	.016^c	-0.277	.250
PDGF-BB	19	-0.215	.363	-0.151	.524	0.043	.857	-0.277	.250
HGF	25	0.624	<.001^a	0.615	<.001^a	0.431	.027^c	-0.235	.257
SCF	25	0.145	.478	0.176	.390	-0.057	.780	0.261	.207
SDF1α	25	0.257	.204	0.314	.117	0.344	.085	0.424	.034^c
sVEGFR1	25	-0.38	.055	-0.365	.066	0.065	.753	0.038	.855
sVEGFR2	25	-0.613	<.001^a	-0.601	.001^b	-0.466	.016^c	-0.431	.031^c

The concentrations of plasma proteins were measured at baseline and at day 8 of lenvatinib treatment, and the percentage change from baseline was analyzed (Spearman’s correlation analysis) in correlation with toxicities and tumor shrinkage. Worst grade of toxicities and maximum tumor shrinkage over the duration of treatment were used for the analysis.
^a P < 0.001.
^b P < 0.01.
^c P < 0.05.

ISSN: 1471-2407